SCIENCE VOLUNTEER	WARNING SIGNS		DONATE
Ý		Q	

# Circulation

This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies.

Click here for more information.

FREE ACCESS ABSTRACT

ARTERIOSCLEROSIS, THROMBOSIS, VASCULAR BIOLOGY SESSION TITLE: DAMPS, INFECTION AND CARDIOVASCULAR METABOLISM

## Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines

Steven R Gundry

Originally published 8 Nov 2021 Circulation. 2021;144:A10712

This article has an expression of concern  $\sim$ 

Expression of Concern: Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning

#### is corrected by $\,\,\smallsetminus\,\,$

Correction to: Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning

## Abstract

This clinic has been using the PULS Cardiac Test (Predictive Health Diagnostics Co., Irvine, CA) a clinically utilized measurement of multiple protein biomarkers, which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS) called the PULS Score. The score is based on changes from the norm of multiple protein inflammatory biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF) which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score. The PULS score has been measured every 3-6 months in our patient population for 8

X

Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines | ....

years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, we tracked the changes of the PULS score and three of the inflammatory markers it measures in all of our patients consecutively receiving these vaccines.

This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a previously scheduled PULS test drawn from 2 to 10 weeks following the 2<sup>nd</sup> mRNA COVID shot and was compared to the pt's PULS test drawn 3 to 5 months previously pre-shot. Each vac pt's PULS score and inflammatory marker changes were compared to their pre-vac PULS score, thus serving as their own control. There was no comparison made with unvaccinated patients or pts treated with other vaccines.

Baseline IL-16 increased from 35+/-20 above the norm to 82 +/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46+/-24 above the norm post vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post vac. These changes resulted in an increase of the pre vac PULS score of predicted 11% 5 yr ACS risk to a post vac PULS score of a predicted 25% 5 yr ACS risk, based on data which has not been validated in this population. No statistical comparison was done in this observational study.

In conclusion, the mRNA vacs numerically increase (but not statistically tested) the markers IL-16, Fas, and HGF, all markers previously described by others for denoting inflammation on the endothelium and T cell infiltration of cardiac muscle, in a consecutive series of a single clinic patient population receiving mRNA vaccines without a control group.

### Footnotes

Author Disclosures: For author disclosure information, please visit the AHA Scientific Sessions 2021 Online Program Planner and search for the abstract title.

# <

∧ Back to top

#### >

# Circulation

#### **AHA** Journals

Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)

Circulation

Circ: Arrhythmia and Electrophysiology

Circ: Genomic and Precision Medicine

Circ: Cardiovascular Imaging

Circ: Cardiovascular Interventions

Circ: Cardiovascular Quality & Outcomes

Circ: Heart Failure

Circulation Research

Hypertension

Stroke

Stroke: Vascular and Interventional Neurology

Journal of the American Heart Association (JAHA)
--

#### Journal Information

About Editorial Board Reprints Customer Service and Ordering Information AHA Journals RSS Feeds For International Users Institutions/Librarians FAQ For Subscribers Subscriber Help Wolters Kluwer Privacy Policy

#### Subjects

All Subjects Arrhythmia and Electrophysiology Basic, Translational, and Clinical Research Critical Care and Resuscitation Epidemiology, Lifestyle, and Prevention Genetics Heart Failure and Cardiac Disease Hypertension Imaging and Diagnostic Testing Intervention, Surgery, Transplantation Quality and Outcomes < /

Stroke

Vascular Disease

#### Features

Bridging Disciplines Circulation at Major Meetings Special Themed Issues Global Impact of the 2017 ACC/AHA Hypertension Guidelines Circulation Supplements Cardiovascular Case Series ECG Challenge Hospitals of History On My Mind Podcast Archive - Circulation on the Run - Subscribe to Circulation on the Run - #FITFAVES Circulation Doodle

#### **Resources & Education**

AHA Guidelines and Statements Circulation CME Information for Advertisers

#### For Authors & Reviewers

Instructions for Authors Submission Site Author Reprints \/

 $\sim$ 

 $\checkmark$ 



# American Heart Association®

**National Center** 7272 Greenville Ave. Dallas, TX 75231

Customer Service 1-800-AHA-USA-1

1-800-242-8721 Local Info Contact Us

#### **ABOUT US**

About the AHA/ASA	>
2016-17 Annual Report	>
AHA Financial Information	>
Careers	>
SHOP	>
Latest Heart and Stroke News	>
AHA/ASA Media Newsroom	>
Global Programs	>

#### **OUR SITES**

American Heart Association	>
American Stroke Association	>
Professional Heart Daily	>

More Sites

TAKE ACTION	
Advocate	>
Donate	>
Planned Giving	>
Volunteer	>

#### **ONLINE COMMUNITIES**

AFib Suppo	ort
------------	-----

**Garden Community** 

Patient Support Network

Privacy Policy Copyright Ethics Policy Conflict of Interest Policy Linking Policy Diversity Careers

Suppliers & Providers Accessibility Statement State Fundraising Notices

© American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is qualified 501(c)(3) tax-exempt organization.

\*Red Dress ™ DHHS, Go Red ™; AHA; National Wear Red Day® is registered trademark.



>

>

>

>